New fund · Healthcare & Life Sciences

Kapiva launches Rs 50 crore innovation fund

By Startup Enthusiast · 23 January 2026

What they do

Kapiva sells Ayurvedic supplements, gummies, juices, teas, and skincare with over 100 products

It commits up to Rs 50 crore for an innovation fund supporting research from early-stage to near-commercialisation

The fund draws from Kapiva's recent $60 million Series D round, and the company is preparing for an IPO

Kapiva has launched an innovation fund with a commitment of up to Rs 50 crore.
The fund supports projects from early research to near-commercialisation.
Cheque sizes range from Rs 50 lakh for early-stage research to Rs 4-6 crore for late-stage programmes.
Focus areas include novel formulations, standardisation, phytochemistry, AI applications in Ayurveda, and clinical studies.
Eligible applicants are research institutions, PhD scholars, clinicians, hospitals, labs, incubators, and early-stage startups.
Applications open via a dedicated portal; proposals are evaluated by Kapiva's R&D leadership and external experts.
Kapiva offers capital, mentorship, access to clinical and research infrastructure, and regulatory guidance.
Kapiva plans to expand its R&D facility in Bengaluru as part of the initiative.

The fund aims to make Ayurveda outcome-driven and evidence-backed, according to co-founder Ameve Sharma.
Capital for the fund is drawn from Kapiva's most recent fundraise – a $60 million Series D round in September 2025.
Kapiva is preparing for an IPO and plans to go public in the next two to three years.
The company already runs in-house R&D with clinical trials and collaborates with institutions like THSTI and Manipal Hospitals.

Kapiva sells Ayurvedic nutrition and wellness products including supplements, gummies, capsules, juices, teas, and skincare.
It has over 100 products and offers consultations with Ayurvedic doctors.
Top categories are diabetes care, gym and sports nutrition, energy, liver and heart health; diabetes supplements are the highest-selling.
Sales channels include a D2C website, online marketplaces, and offline retail stores.
Kapiva runs in-house R&D with clinical trials on flagship products and a dedicated research team.
It collaborates with THSTI (Ministry of Science and Technology), Manipal College of Pharmaceutical Sciences, and Manipal Hospitals.

Kapiva plans to expand its R&D facility in Bengaluru as part of the initiative.
Kapiva is preparing for an IPO and plans to go public in the next two to three years.

Product: D2C ayurveda brand
Customers: Consumers seeking evidence-based ayurvedic nutrition and wellness products
How it makes money: Direct-to-consumer brand selling ayurvedic supplements, gummies and skincare online
What sets it apart: Modern positioning of ayurveda with clinical validation and wide retail reach